MENLO PARK, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that it will host a live conference call and webcast at 8:00 a.m. ET (5:00 a.m. PT) on Tuesday, November 12, 2019 to report its third quarter 2019 financial results and provide a corporate update.
The live call may be accessed by dialing (866) 953-0780 for domestic callers or (630) 652-5854 for international callers and providing the conference ID number 7667736. An audio webcast of the call will also be available under “Events & Presentations” in the Investors section of Forty Seven’s website at www.fortyseveninc.com. A replay of the webcast will be available on the Forty Seven website approximately two hours after the conference call, and will be available for 90 days following the event.
About Forty Seven Inc.
Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven’s lead program, magrolimab, is a monoclonal antibody against the CD47 receptor, a “don’t eat me” signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in multiple clinical studies in patients with myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin’s lymphoma, ovarian cancer and colorectal carcinoma.
For more information please visit www.fortyseveninc.com or contact firstname.lastname@example.org.
For journalist enquiries please contact Sarah Plumridge at email@example.com or phone (312) 506-5218.
For investor enquiries please contact Hannah Deresiewicz at Stern Investor Relations Inc. at firstname.lastname@example.org or phone (212) 362-1200.